论文部分内容阅读
为研究血脂康的降脂作用强度，对１０８例原发性高脂血症患者，按血脂水平分层配对随机分组，５３例服血脂康，５５例服辛伐他丁作为对照。８周末两组血清总胆固醇（ＴＣ）分别下降２３．０％与２３．３％，低密度脂蛋白胆固醇（ＬＤＬ－Ｃ）分别下降２８．０％与２９．５％，甘油三酯（ＴＧ）分别下降２８．１％与２９．５％。各自与治疗前相比差异均有显著性（Ｐ均＜０．００１），但两组间对比差异无显著性（Ｐ均＞０．０５）。血脂康耐受性好，无明显不良反应。提示血脂康是与辛伐他丁疗效相似的国产高效血脂调节剂。
In order to study the lipid-lowering effect of Xuezhikang, 108 patients with primary hyperlipidemia were randomly divided into three groups according to the level of lipid: 53 with Xuezhikang and 55 with simvastatin. Serum total cholesterol (TC) decreased by 23.0% and 23.3%, while low density lipoprotein cholesterol (LDL-C) decreased by 28.0% and 29.5%, triglyceride (TG) Down 28.1% and 29.5% respectively. The difference between the two groups was significant (P <0.001), but there was no significant difference between the two groups (P> 0.05). Xuezhikang good tolerance, no significant adverse reactions. Tip Xuezhikang and simvastatin efficacy similar to the domestic high blood lipid regulator.